Application of ligusticum cyclopropyrianum in preparation of medicine for preventing and treating diabetic nephropathy

By using ciprofloxacin to improve blood glucose regulation and reduce inflammatory factors, the shortcomings of existing technologies in the treatment of diabetic nephropathy and renal fibrosis have been overcome, achieving effective prevention and treatment of diabetic nephropathy with few side effects and high safety.

CN118924741APending Publication Date: 2024-11-12HARBIN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411145342.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Current technology lacks effective drugs for treating diabetic nephropathy and renal fibrosis. Existing drugs have limited effects, low safety, numerous adverse reactions, and are not ideal for reversing renal fibrosis.

Method used

Using cyprostaglandin as the main active ingredient, drugs for the prevention and treatment of diabetic nephropathy are prepared by improving blood glucose regulation, reducing insulin resistance, and lowering the levels of inflammatory factors and profibrotic factors. These drugs include various dosage forms and routes of administration.

Benefits of technology

Ciprofloxacin significantly improves kidney damage caused by hyperglycemia, inhibits the process of kidney fibrosis, has few side effects, high safety, and has a significant preventive and therapeutic effect on diabetic nephropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924741A_ABST
    Figure CN118924741A_ABST
Patent Text Reader

Abstract

The invention provides an application of ligusticum cipatorii in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biological medicines. According to the medicine for preventing and treating the diabetic nephropathy, ligusticum sinense is a main active ingredient of the medicine for preventing and treating the diabetic nephropathy, and the medicine for preventing and treating the diabetic nephropathy further comprises pharmaceutically acceptable auxiliary materials. The ligusticum cyclopropyrianum can improve kidney injury caused by body hyperglycemia and inhibit the renal fibrosis process by improving the blood sugar regulation capacity, relieving insulin resistance, reducing the inflammatory factor level and / or reducing the profibrosis factor, has small side effects and high safety, and has an obvious prevention and treatment effect on diabetic nephropathy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to the application of ciprofloxacin in the preparation of drugs for preventing and treating diabetic nephropathy. Background Art

[0002] Diabetic kidney disease (DKD) is one of the most common microvascular complications in patients with diabetes. Apoptosis and loss of tubular epithelial cells, massive infiltration of inflammatory cells, and renal interstitial fibrosis are the main pathological features of diabetic nephropathy, and are also important factors that accelerate the progression of diabetic nephropathy. Renal fibrosis is a manifestation of end-stage diabetic nephropathy, which is manifested as gradual and irreversible scarring of the glomeruli, followed by fibrosis in the tubular interstitial region. If renal fibrosis is not treated in time, the kidneys will be further damaged and develop into diabetic renal failure.

[0003] At present, there is no direct and effective treatment for diabetic nephropathy and renal fibrosis. Usually, blood sugar, blood pressure and blood lipid regulating drugs (including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers) and renin-angiotensin-aldosterone system (RAS) inhibitors (including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers) are used for treatment. However, these drugs have a single direction of action, low safety, many adverse reactions, and unsatisfactory reversal effects on renal fibrosis. Therefore, finding an effective treatment and prevention drug for diabetic nephropathy and renal fibrosis has become a hot topic of research at home and abroad.

[0004] Ligustilide (LIG) is a phthalide derivative derived from natural medicines such as Chinese herbal medicines Angelica sinensis and Chuanxiong. It has been reported to have pharmacological effects such as anti-apoptosis, anti-inflammatory, and antioxidant, especially for the kidneys. However, due to the structural instability of ligustilide, it is prone to oxidation, polymerization and degradation reactions, and has poor drugability, which limits its clinical application. In order to achieve the scientific goal of stabilizing ligustilide, the target compound ciprofloxacin was derived from the chemical structure of ligustilide. The synthetic route of ciprofloxacin is as follows:

[0005]

[0006] The compound is a white crystalline powder, slightly soluble in water, and easily soluble in organic solvents such as methanol, ethanol, acetone, and ethyl acetate. The molecular formula of ciprofloxacin (LIGc) is C 15 H 21 NO2, molecular weight is 247, and the molecular structure is as follows:

[0007]

[0008] At present, there are no reports on the application of ciprofloxacin in diabetic nephropathy and diabetes-induced renal damage and renal fibrosis. Summary of the invention

[0009] In view of the above-mentioned deficiencies, the present invention provides the use of ciprofloxacin in the preparation of drugs for preventing and treating diabetic nephropathy. In the present invention, ciprofloxacin is the main active ingredient of the drug for preventing and treating diabetic nephropathy, and the drug for preventing and treating diabetic nephropathy also includes pharmaceutically acceptable excipients. The ciprofloxacin can improve kidney damage caused by hyperglycemia and inhibit the process of renal fibrosis by improving blood sugar regulation ability, reducing insulin resistance, reducing the level of inflammatory factors and / or reducing profibrotic factors. It has few side effects, high safety, and has obvious preventive and therapeutic effects on diabetic nephropathy.

[0010] The technical solution of the present invention is:

[0011] In one aspect, the present invention provides a use of ciprofloxacin in the preparation of a drug for preventing and treating diabetic nephropathy, wherein the ciprofloxacin has a structure as shown in Formula 1:

[0012]

[0013] Specifically, the ciprofloxacin is the main active ingredient of the drug for preventing and treating diabetic nephropathy.

[0014] Specifically, the drug for preventing and treating diabetic nephropathy also includes pharmaceutically acceptable excipients.

[0015] Preferably, the pharmaceutically acceptable excipients include, but are not limited to: solvents, emulsifiers, disintegrants, solubilizers, antioxidants, pH regulators, osmotic pressure regulators, antibacterial agents, diluents, wetting agents, adhesives and / or film-forming agents.

[0016] Specifically, the dosage forms of the drug for preventing and treating diabetic nephropathy include, but are not limited to, tablets, capsules, soft capsules, granules, powders, pills, gel candies, powders, oral liquids or drops.

[0017] Specifically, the administration route of the drug for preventing and treating diabetic nephropathy includes a gastrointestinal administration route or a parenteral administration route.

[0018] Preferably, the gastrointestinal administration route includes but is not limited to oral administration.

[0019] Preferably, the non-intestinal administration route includes: injection, respiratory tract administration, skin administration, mucosal administration or cavity administration.

[0020] Specifically, the drug for preventing and treating diabetic nephropathy achieves the effect of preventing and treating diabetic nephropathy by improving blood sugar regulation ability, reducing insulin resistance, reducing inflammatory factor levels and / or reducing profibrotic factors.

[0021] Specifically, the diabetic nephropathy includes type Ⅰ diabetic nephropathy or type Ⅱ diabetic nephropathy.

[0022] Preferably, the diabetic nephropathy is type 1 diabetic nephropathy.

[0023] Specifically, the diabetic nephropathy includes glomerular sclerosis, glomerular mesangial proliferation, tubulointerstitial lesions, renal interstitial fibrosis, tubular atrophy, hyalinization of the efferent artery or renal microvascular sclerosis.

[0024] Preferably, the diabetic nephropathy is renal interstitial fibrosis.

[0025] Specifically, the drug for preventing and treating diabetic nephropathy can be administered in combination with one or more of anti-diabetic drugs, anti-thrombotic drugs, anti-hypertensive drugs, anti-lipid drugs, anti-cardiovascular and cerebrovascular disease drugs, and anti-infective drugs.

[0026] In another aspect, the present invention provides a drug for preventing and treating diabetic nephropathy, the drug comprising ciprofloxacin, the ciprofloxacin having a structure as shown in Formula 1;

[0027]

[0028] Specifically, the ciprofloxacin is the main active ingredient of the drug.

[0029] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0030] Preferably, the pharmaceutically acceptable excipients include, but are not limited to: solvents, emulsifiers, disintegrants, solubilizers, antioxidants, pH regulators, osmotic pressure regulators, antibacterial agents, diluents, wetting agents, adhesives and / or film-forming agents.

[0031] Specifically, the dosage form of the drug includes but is not limited to: tablets, capsules, soft capsules, granules, powders, pills, gel candies, powders, oral liquids or drops.

[0032] Specifically, the dosage form of the drug includes but is not limited to: tablets, capsules, soft capsules, granules, powders, pills, gel candies, powders, oral liquids or drops.

[0033] Specifically, the administration route of the drug includes a gastrointestinal administration route or a parenteral administration route.

[0034] Preferably, the gastrointestinal administration route includes but is not limited to oral administration.

[0035] Preferably, the non-intestinal administration route includes: injection, respiratory tract administration, skin administration, mucosal administration or cavity administration.

[0036] Specifically, the drug achieves the preventive and therapeutic effects of diabetic nephropathy by improving blood sugar regulation ability, reducing insulin resistance, lowering inflammatory factor levels and / or reducing profibrotic factors.

[0037] Specifically, the diabetic nephropathy includes type Ⅰ diabetic nephropathy or type Ⅱ diabetic nephropathy.

[0038] Preferably, the diabetic nephropathy is type 1 diabetic nephropathy.

[0039] Specifically, the diabetic nephropathy includes glomerular sclerosis, glomerular mesangial proliferation, tubulointerstitial lesions, renal interstitial fibrosis, tubular atrophy, hyalinization of the efferent artery or renal microvascular sclerosis.

[0040] Preferably, the diabetic nephropathy is renal interstitial fibrosis.

[0041] Specifically, the drug can be administered in combination with one or more of anti-diabetic drugs, anti-thrombotic drugs, anti-hypertensive drugs, anti-lipidemia drugs, anti-cardiovascular and cerebrovascular disease drugs, and anti-infective drugs.

[0042] The beneficial effects of the present invention are:

[0043] Ciprofloxacin can improve kidney damage caused by hyperglycemia and inhibit the process of renal fibrosis by improving blood sugar regulation ability, reducing insulin resistance, lowering the level of inflammatory factors and / or reducing pro-fibrotic factors. It has few side effects, high safety, and has obvious preventive and therapeutic effects on diabetic nephropathy. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 To provide a modeling method and grouping for diabetic nephropathy.

[0045] Figure 2This is a graph showing the effect of ciprofloxacin on blood glucose level and renal filtration function in mice with diabetic nephropathy; A in the figure is the fasting blood glucose value of each group of mice at the 8th week of drug administration; B is the line graph of oral glucose tolerance test of each group of mice; C is the area under the curve statistics of OGTT line graph; D is the line graph of insulin tolerance test of each group of mice; E is the area under the curve statistics of ITT line graph; F is the serum creatinine value determination of each group of mice; G is 24-hour urine volume; H is 24-hour albuminuria; ns represents no significant difference; * represents p<0.05 compared with STZ group; ** represents p<0.01 compared with STZ group; *** represents p<0.001 compared with STZ group; **** represents p<0.0001 compared with STZ group; #### represents p<0.0001 compared with control group.

[0046] Figure 3 This is a tissue PAS staining section showing the effect of ciprofloxacin on renal tissue morphology in mice with diabetic nephropathy.

[0047] Figure 4 This is a tissue HE staining section showing the effect of ciprofloxacin on the renal tissue morphology of diabetic nephropathy mice.

[0048] Figure 5 This is a tissue MASSON staining section showing the effect of ciprofloxacin on the renal tissue morphology of diabetic nephropathy mice.

[0049] Figure 6 This is the tissue CD68 immunohistochemical staining section diagram and positive area statistical diagram of the effect of ciprofloxacin on renal tissue morphology in mice with diabetic nephropathy; in the figure, *** represents p<0.001 compared with the STZ group; **** represents p<0.0001 compared with the STZ group; #### represents p<0.0001 compared with the control group.

[0050] Figure 7 This is the effect of ciprofloxacin on the mRNA levels of inflammatory infiltrating factors in diabetic nephropathy mice; ns represents no significant difference; * represents p < 0.05 compared with the STZ group; ** represents p < 0.01 compared with the STZ group; *** represents p < 0.001 compared with the STZ group; #### represents p < 0.0001 compared with the control group.

[0051] Figure 8 This is a graph showing the effect of ciprofloxacin on the protein expression levels of inflammatory infiltrating factors in diabetic nephropathy mice.

[0052] Fig. 9This is the tissue FN immunohistochemical staining section diagram and positive area statistical diagram of the effect of ciprofloxacin on renal tissue morphology in diabetic nephropathy mice; in the figure, **** represents p<0.0001 compared with the STZ group; #### represents p<0.0001 compared with the control group.

[0053] Fig.10 This is a graph showing the effect of ciprofloxacin on the mRNA and protein levels of renal fibrosis-promoting factors in diabetic nephropathy mice; in the figure, ** represents p<0.01 compared with the STZ group; **** represents p<0.0001 compared with the STZ group; #### represents p<0.0001 compared with the control group. DETAILED DESCRIPTION

[0054] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0055] Example 1 Effect of Ciprofloxacin on Mice with Diabetic Nephropathy

[0056] 1.1 Modeling and grouping

[0057] SPF grade 6-8 week old male C57BL / 6 mice were fed a high fat diet (18% fat, 50% carbohydrates, 19% protein) for 1 week, and then intraperitoneally injected with streptozotocin (STZ, 40 mg / kg) for 5 consecutive days. One week later, the fasting blood glucose concentration was measured, and if it exceeded 11.1 mmol / L, it was identified as diabetic mice (DM mice).

[0058] The diabetic mice were randomly divided into 4 groups (n=8), including the diabetic nephropathy model group (STZ group), the positive group (Losartan group), the LIGc low-dose group (LIGc-L group), and the LIGc high-dose group (LIGc-H group).

[0059] Losartan group: Losartan 30 mg / kg / d was administered orally for 8 weeks;

[0060] LIGc-L group: 20 mg / kg / d of ciprofloxacin was administered by intragastric gavage for 8 weeks;

[0061] LIGc-H group: intragastric administration of 40 mg / kg / d of ciprofloxacin for 8 consecutive weeks;

[0062] STZ group: The patients were intragastrically gavaged with an equal volume of PBS for 8 consecutive weeks.

[0063] The control group (n=8) was composed of healthy mice fed with normal feed. Figure 1 Each mouse was placed in a metabolic cage for 24 h before sampling to collect urine samples. Finally, blood samples were collected by eye bleeding after anesthesia.

[0064] 1.2 Blood glucose level and renal filtration function measurement

[0065] During the experiment, about 1 mm of the mouse's tail was cut off every seven days to allow the caudal venous blood to flow out of the mouse's tail. The first drop of blood that came out of the tail was wiped clean with a cotton swab, and the second drop of blood was dropped on the test paper. The fasting blood sugar of the mouse was tested and recorded using a blood glucose meter.

[0066] After 8 weeks of administration, the mice were fasted for 8 hours but not water before sampling, and the fasting blood glucose, oral glucose tolerance and insulin tolerance of the mice were measured. In order to better compare the oral glucose tolerance and insulin tolerance of each group of mice, the curve statistics of the oral glucose tolerance and insulin tolerance line graphs were performed and a one-way analysis of variance was performed. The blood creatinine and urine protein of the mice were measured by using a creatinine determination kit and a urine protein quantitative test kit.

[0067] Blood sugar levels and kidney filtration function test results such as Figure 2 As shown, there was a significant difference in blood glucose levels between the diabetic nephropathy model group and the control group, indicating that the model was successfully established. Cipro Ligusticum chuanxiong can significantly reduce hyperglycemia in mice induced by STZ injection. The high-dose cipro Ligusticum chuanxiong treatment group reduced blood glucose most significantly, which was better than the low-dose LIGc group, but the low-dose cipro Ligusticum chuanxiong can still significantly reduce the fasting blood glucose level of mice. This shows that the administration of cipro Ligusticum chuanxiong can significantly improve the blood glucose regulation ability of diabetic nephropathy mice and restore the pancreatic β-cell function in diabetic nephropathy mice.

[0068] Serum creatinine and 24-hour urine protein are important indicators of renal function. Increased serum creatinine and 24-hour urine protein often mean decreased renal function. After treatment with ciprofloxacin, the serum creatinine content of diabetic nephropathy mice was significantly reduced, and the 24-hour urine protein content of diabetic nephropathy mice was significantly reduced, showing a significant renal protective effect. Diabetic patients often show polyuria, and high doses of ciprofloxacin can significantly reduce the polyuria of diabetic nephropathy mice.

[0069] The above results indicate that ciprofloxacin can simultaneously improve the blood sugar regulation ability of diabetic nephropathy mice, reduce insulin resistance, and restore the renal function of diabetic nephropathy mice, and has a significant and more comprehensive effect in preventing and treating diabetic nephropathy.

[0070] 1.3 Histopathological examination

[0071] 24 hours after the last administration, kidney tissues of mice in each group were obtained, fixed, dehydrated and embedded, and then sliced ​​to detect kidney damage, glycogen accumulation and fibrosis.

[0072] PAS stained sections Figure 3 As shown, HE staining sections are shown Figure 4 As shown, MASSON stained sections are shown Figure 5 As shown. HE and PAS pathological staining showed that the diabetic nephropathy model group mice had tubular epithelial cell damage, tubular dilatation and atrophy, inflammatory cell infiltration, glomerular hypertrophy, increased mesangial matrix, and glomerular wall adhesion, while ciprofloxacin and losartan could improve tubular epithelial cell damage, tubular dilatation and atrophy, inflammatory cell infiltration, and glomerular hypertrophy, increased mesangial matrix, and glomerular wall adhesion. Masson staining results showed that the renal interstitial collagen deposition in the diabetic nephropathy model group mice was much higher than that in the normal control group. However, treatment with ciprofloxacin and losartan could significantly improve the tubular interstitial collagen deposition in diabetic nephropathy mice. These results indicate that ciprofloxacin and losartan can improve renal pathological changes in diabetic nephropathy mice, reduce inflammatory cell infiltration, and improve renal interstitial fibrosis.

[0073] 1.4 Tissue CD68 immunohistochemical staining

[0074] Effect of Ciprofloxacin on acute inflammatory indicators caused by hyperglycemia In diabetic nephropathy, the infiltration of inflammatory cells plays a very important role in the occurrence and development of renal damage. CD68 is the most reliable marker of macrophages. Inflammatory reactions recruit a large number of macrophages, so high expression of CD68 is often shown in the kidneys of patients with diabetic nephropathy. The present invention uses immunohistochemistry to detect the expression of CD68 in mouse kidneys. The specific steps are as follows:

[0075] Kidney tissue sections of each group of mice were taken and dewaxed according to xylene and decreasing concentrations of alcohol; soaked in distilled water for 5 minutes; repaired with citrate for 15 minutes, cooled to room temperature; soaked in distilled water for 2 minutes; placed at room temperature for 10 minutes with 3% hydrogen peroxide; washed 3 times with PBS; blocked with 1% BSA for 1 hour; added primary antibody F4 / 80 or Ly6G, overnight at 4°C; washed 3 times with PBS; incubated with secondary antibody at room temperature for 2 hours; washed 3 times with PBS; developed with DAB; rinsed with tap water for 10 minutes; stained with hematoxylin for 25 seconds; rinsed with tap water for 15 minutes; dehydrated with increasing concentrations of ethanol, made transparent with xylene, air-dried, and sealed with neutral gum; observed the marker CD68 of macrophages and neutrophils in the sealed sections of liver tissue sections. The positive area was counted by Image J software.

[0076] CD68 immunohistochemical staining sections and positive area results are shown in Figure 6Compared with the mice in the diabetic nephropathy model group, the expression of CD68 in the renal tissue of the mice in the ciprofloxacin and losartan intervention groups was significantly reduced. The statistical results showed that the positive area of ​​CD68 in the kidneys of the mice in the ciprofloxacin and losartan intervention groups was significantly reduced, which indicates that ciprofloxacin can significantly reduce the infiltration of macrophages and the inflammatory response in the kidneys was significantly improved.

[0077] 1.5 Expression levels of mRNA and protein of inflammatory infiltrating factors

[0078] CD68, Ccl-2, F4 / 80, IL-1β, and MCP 1 are important indicators of renal immune cell infiltration. The present invention uses qPCR to detect the mRNA expression levels of CD68, Ccl-2, F4 / 80, and IL-1β, and uses WB to detect the protein expression level of MCP 1. The specific process is as follows:

[0079] The RNA in the homogenized mouse kidney samples was extracted by Trizol method, and the RNA concentration was determined. The extracted RNA samples were amplified using a reverse transcription kit (conditions: 37°C for 15 min, 85°C for 5 s) to obtain cDNA. The samples were mixed evenly according to the qPCR loading system and added to 384 qPCR wells in the loading order. The wells were placed in a fluorescent quantitative PCR instrument (Roche LightCycler 480) for detection. After the detection, the cDNA was obtained according to formula 2 -ΔΔCT Calculate the relative mRNA value of each sample.

[0080] qPCR test results Figure 7 As shown in Figure 2, Ccl-2, F4 / 80, Il-1β, and CD68 in the renal tissue of mice in the diabetic nephropathy model group were significantly increased at the mRNA level. After treatment with losartan and ciprofloxacin, the expression levels of Ccl-2, F4 / 80, Il-1β, and CD68 were all reduced to a certain extent. The results of WB assay are shown in Figure 2. Figure 8 As shown in the figure, MCP 1 protein level in diabetic nephropathy model mice increased, which was improved after treatment with losartan and ciprofloxacin. Therefore, ciprofloxacin can improve the development of diabetic nephropathy by inhibiting the infiltration of inflammatory cells in the kidneys of diabetic nephropathy mice.

[0081] 1.6 Tissue FN immunohistochemical staining and determination of renal fibrosis promoting factor levels

[0082] The main pathological manifestations of tubulointerstitial fibrosis are the progressive reduction of tubular epithelial cells and the abnormal accumulation of ECM. Myofibroblasts are the main cell synthesizers of ECM and can produce a large amount of collagen. The main components of ECM include FN and type IV collagen (Collagen IV).

[0083] (1) Tissue FN immunohistochemical staining sections

[0084] The present invention uses immunohistochemistry to detect the expression of FN in mouse kidneys, and uses Image J to perform statistics on the positive area.

[0085] Tissue FN immunohistochemical staining sections are shown in Fig. 9 The expression of FN in the kidney tissue of mice in the diabetic nephropathy model group increased significantly, indicating that a large amount of abnormal ECM accumulation occurred in the kidney tissue of mice, a large increase in adhesion proteins, and a deepening of fibrosis. After intervention with ciprofloxacin and losartan, the expression of FN in the kidney tissue of mice with diabetic nephropathy decreased significantly, and the positive area of ​​FN was significantly reduced after statistics.

[0086] (2) Determination of renal fibrosis promoting factor levels

[0087] To further evaluate the degree of fibrosis in diabetic nephropathy mice, the expression of FN and Col 4α1 was detected by qPCR technology, and the expression of FN was detected by WB technology.

[0088] The results of the test are as follows Fig.10 As shown in the data, the expression of FN and Col4α1 in the renal tissue of diabetic nephropathy model mice was significantly increased at the mRNA level. Similarly, WB test results showed that the expression of FN was significantly increased at the protein level. After treatment with losartan and ciprofloxacin, the expression of FN and Col4α1 was downregulated to a certain extent. The increase of FN and Col4α1 is an important feature of renal interstitial fibrosis. Ciprofloxacin can inhibit the expression of FN and Col4α1 and thus intervene in diabetic nephropathy. This indicates that ciprofloxacin can improve the development of diabetic nephropathy by inhibiting renal interstitial fibrosis in diabetic nephropathy mice.

[0089] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or some technical features can be replaced by equivalents without departing from the spirit of the technical solution of the present invention, which should be included in the scope of the technical solution for protection of the present invention.

Claims

1. The use of ciprofloxacin in the preparation of a drug for preventing and treating diabetic nephropathy, characterized in that: The ciprofloxacin has a structure as shown in Formula 1:

2. The use according to claim 1, characterized in that: The ciprofloxacin is the main active ingredient of the drug for preventing and treating diabetic nephropathy.

3. The use according to claim 1, characterized in that: The drug for preventing and treating diabetic nephropathy also includes pharmaceutically acceptable excipients.

4. The use according to claim 1, characterized in that: The dosage forms of the drug for preventing and treating diabetic nephropathy include tablets, capsules, soft capsules, granules, powders, pills, gel candies, powders, oral liquids or drops.

5. The use according to claim 1, characterized in that: The administration route of the drug for preventing and treating diabetic nephropathy includes a gastrointestinal administration route or a non-gastrointestinal administration route.

6. The use according to claim 1, characterized in that: The drug for preventing and treating diabetic nephropathy achieves the effect of preventing and treating diabetic nephropathy by improving blood sugar regulation ability, reducing insulin resistance, reducing inflammatory factor levels and / or reducing profibrotic factors.

7. The use according to claim 1, characterized in that: The diabetic nephropathy includes type Ⅰ diabetic nephropathy or type Ⅱ diabetic nephropathy.

8. The use according to claim 1, characterized in that: The diabetic nephropathy includes glomerular sclerosis, glomerular mesangial hyperplasia, tubulointerstitial lesions, renal interstitial fibrosis, tubular atrophy, hyalinization of the efferent artery or renal microvascular sclerosis.

9. The use according to claim 1, characterized in that: The drug for preventing and treating diabetic nephropathy can be administered in combination with one or more of anti-diabetic drugs, anti-thrombotic drugs, anti-hypertensive drugs, anti-lipid drugs, anti-cardiovascular and cerebrovascular disease drugs, and anti-infective drugs.

10. A drug for preventing and treating diabetic nephropathy, characterized in that: The drug includes ciprofloxacin, and the ciprofloxacin has a structure as shown in Formula 1;